Associated Genetic Biomarkers
CD44 molecule (Indian blood group) (CD44) is a gene that encodes a protein that functions in cell-cell interactions, cell adhesion, cell migration, lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as stomach cancer, endometrial cancer, and lung cancer.
CD44 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CD44 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with CD44 status in the inclusion eligibility criteria most commonly target ovarian carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is CD44 Expression .
Spl-108 and paclitaxel are the most frequent therapies in trials with CD44 as an inclusion criteria .
Significance of CD44 in Diseases
Ovarian Carcinoma +
CD44 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD44 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.